Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue (2018 - 2026)

Arcturus Therapeutics Holdings has reported Current Deferred Revenue for 9 years, with the latest figure at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 39.94% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 39.94% YoY), and the FY2025 full-year result was $8.2 million, down 57.74% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $7.6 million, down from $8.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $71.5 million in Q1 2024, with the low at $4.7 million in Q3 2022.
• Historically, Current Deferred Revenue has averaged $28.9 million across 5 years, with a median of $26.9 million in 2024.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue slumped 91.92% — and 2023, when it soared 775.6%.
• Arcturus Therapeutics Holdings' Current Deferred Revenue stood at $28.6 million in 2022, then soared by 56.48% to $44.8 million in 2023, then plunged by 56.47% to $19.5 million in 2024, then sank by 57.74% to $8.2 million in 2025, then fell by 7.71% to $7.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $7.6 million (Q1 2026), $8.2 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.